# Intravenous Thrombolysis, Endovascular Treatment, or Bridging Therapy for Medium Vessel Occlusion Stroke Within 24 Hours

Study · id `cardio:ct-nct07931807` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07931807](<https://clinicaltrials.gov/study/NCT07931807>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07931807

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1395 participants.

## Technical summary

Registry record NCT07931807. Randomized; single masking; primary purpose treatment. Start 2026-12 (anticipated); primary completion 2029-04-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1395 participants (planned count; ClinicalTrials.gov record NCT07931807, source copy `cardio:ctgov-nct07931807-2026-11-12`, retrieved 2026-11-18)
- Planned start: 2026-12 (anticipated) (ClinicalTrials.gov record NCT07931807, source copy `cardio:ctgov-nct07931807-2026-11-12`, retrieved 2026-11-18)
- Primary completion: 2029-04-30 (anticipated) (ClinicalTrials.gov record NCT07931807, source copy `cardio:ctgov-nct07931807-2026-11-12`, retrieved 2026-11-18)
- Completion: 2029-04-30 (anticipated) (ClinicalTrials.gov record NCT07931807, source copy `cardio:ctgov-nct07931807-2026-11-12`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT07931807, source copy `cardio:ctgov-nct07931807-2026-11-12`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07931807-2026-11-12`, retrieved 2026-11-18)

## The registry's words

- Brief title: Intravenous Thrombolysis, Endovascular Treatment, or Bridging Therapy for Medium Vessel Occlusion Stroke Within 24 Hours
- Acronym: ORIENTAL-MeVO2
- Condition: Medium Vessel Occlusion Stroke (MeVO)
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Tenecteplase
- Intervention (Procedure): Endovascular Treatment
- Lead sponsor: The First Affiliated Hospital of University of Science and Technology of China
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Tenecteplase (`cardio:tenecteplase`)
- Registry lists this organization as the lead sponsor: The First Affiliated Hospital of University of Science and Technology of China (`cardio:org-the-first-affiliated-hospital-of-university-of-science-and-03d159`)

## Provenance

Content hash: ec1507e68ae401ccfcb7d14367760de94bc2606fe2ca5d826347674c25813492
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
